C1N101 ANTIBODY COMPOSITIONS AND METHODS OF USE ALONE AND IN COMBINATION WITH PROSTATE SPECIFIC ANTIGEN AND OTHER CANCER MARKERS

摘要

This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Clnl01 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Clnl01 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (C1nl0l) antibodies that bind to Clnl0l in vivo. The invention also encompasses compositions comprising an anti-C1nl0l antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-C1nl0l antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-C1nl0l antibodies. The invention encompasses a method of producing the anti-C1nl0I antibodies. Other aspects of the invention are a method of killing an Clnl0l -expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101 -expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.